Case report demonstrates sustained disease control in metastatic urothelial carcinoma after managing adverse events from antibody-drug conjugate treatment.
Introduction Enfortumab vedotin (EV), an antibody–drug conjugate targeting Nectin-4, has become a standard treatment option for metastatic urothelial carcinoma (mUC) following failure of platinum-based chemotherapy and immune checkpoint inhibitors. However, adverse events such as skin toxicity often necessitate dose modification or temporary discontinuation. Case Presentation We report the case of a 72-year-old woman with mUC who achieved a long-team partial response to EV despite experiencing grade 2 skin toxicity that required temporary treatment interruption. After symptom resolution, EV was successfully reintroduced at a reduced dose, and clinical response was maintained. Conclusion Temporary discontinuation of EV due to adverse events (AEs) followed by intermittent reintroduction resulted in long-term disease control in this patient with mUC. This case suggests that rechallenging EV after treatment interruption may be a feasible approach in selected patients, underscoring the importance of careful AE management in real-world practice.
No takes yet. Share an insight, caveat, or question.
Shirotake et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: